If the 'placebo' does its job, then the playing field is levelled. Due to 'blindness', no one knows whether they are receiving the drug or not and even with or without drug efficacy most could perceive improvement and thus go on with the trial.
If the 'placebo' has little effect AND the drug is efficacious, then in this simplistic case 50% would drop out and 50% would continue.
The reality is much more complex than the two hand picked scenarios above and will only be revealed by analysis of the LAVENDER blinded trial data. However, the number of LILAC enrollments is perhaps not such a lay down misere indicator of drug efficacy as it may appear at face value. Anything under 50% enrollment would be a worrying sign, but above that .... who knows?
NEU Price at posting:
$2.08 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)